Boron-Containing Compounds: Identification, Synthesis, Biological Actions and Pharmacology

Dear Colleagues,

Boron-containing compounds (BCCs) are gaining increasing attention in drug development due to their promising therapeutic potential. Currently, five BCCs—bortezomib, tavaborole, ixazomib, crisaborole, and vaborbactam—have been successfully developed into marketed drugs. Additionally, naturally occurring BCCs, such as boric acid, sodium tetraborate, and fructoborate, have shown bioactivity and have been proposed as pharmacophores for various medical applications. While many BCCs have been predominantly explored for their antimicrobial and anticancer properties, emerging research suggests they may hold therapeutic potential across a wider range of biomedical fields.

This Special Issue aims to highlight and compile new research on BCCs, whether discovered in nature or synthesized in the laboratory. We welcome studies focusing on the chemistry and bioactivity of these compounds, as well as investigations into their pharmacological (pharmacodynamics/pharmacokinetics) profiles, including those already in clinical use. We are also interested in medicinal chemistry studies involving BCCs, including but not limited to the design of novel formulations, biomaterials, and compounds with potential applications in the prevention, diagnosis, or treatment of diseases.

This Special Issue will serve as a platform to highlight recent advancements in the medicinal chemistry of boron-containing compounds and their evolving role in addressing unmet medical needs.

We look forward to your valuable contributions to this exciting and rapidly growing field.

Dr. Marvin Antonio Soriano-Ursúa
Dr. Andrei Biță
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.